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Abstract: Recombinant monoclonal antibodies (Ab’s) have widespread application as research 
tools, diagnostic reagents and as biotherapeutics. Whilst studying the cellular molecular switch 
protein m-ras, a recombinant monoclonal antibody to m-ras was generated for use as a research 
tool. Antibody genes from a single rabbit B cell secreting IgG to an m-ras specific peptide 
sequence were expressed in mammalian cells and monoclonal rabbit IgG binding was 
characterized by ELISA and peptide array blotting. Although the monoclonal Ab was selected for 
specificity to m-ras peptide it also bound to both recombinant full-length m-ras and h-ras proteins. 
The cross reactive binding of the monoclonal Ab to h-ras was defined by peptide array blot 
revealing that the Ab showed preference for peptide sequences containing multiple positively 
charged amino acid residues. These data reinforce the concept of antibody multispecificity through 
multiple interactions of the Ab paratope with diverse polypeptides. They also emphasize the 
importance of immunogen and Ab selection processes when generating recombinant monoclonal 
Ab’s. 
Keywords: Recombinant monoclonal antibody; specificity; polyreactivity; ras 
 
Introduction 
Antibodies (Ab’s) are glycoproteins of the immunoglobulin superfamily that are produced by B 
lymphocytes to foreign antigens (Ag’s) (for review see [1]). During immune responses Ab’s are 
produced in a polyclonal fashion to Ag’s by numerous B cell although individual B cells produce a 
single Ab clonotype. Polyclonal Ab’s therefore refer to the mixture of Ab’s found in biological 
fluids, such as serum, that are produced by many B cells. Thus, polyclonal Ab’s are defined as 
having a large number of specificities but tend to be enriched for a particular Ag, often following 
immunization or exposure to the Ag [2]. Importantly, in 1975 the advent of hybridoma technology 
permitted the isolation of B cell clones allowing for continued production of monoclonal Ab’s [3]. 
Thus, monoclonal Ab’s are a single clone of Ab’s thought as being superior to polyclonal Ab’s due 
to their selectivity and specificity for single Ag’s. Over the last forty years, exploitation of their 
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ability to specifically recognise, immobilise, destroy or clear such Ag’s has seen both polyclonal 
and monoclonal Ab’s transformed into diagnostic markers, laboratory tools and powerful 
therapeutics and prophylactics for human diseases [4-6]. These Ab’s are usually of the IgG isotype 
due to their generalised function in vitro and relatively long half-life and superior effector function 
in vivo as opposed to that of the IgA and IgM isotypes which have more specialised functions. 
Ab’s have enjoyed great utility in numerous applications within research laboratories, 
diagnostic laboratories and in clinical settings [7]. Laboratory methods such as 
immunohistochemistry, immunofluorescence, western blot, immunoprecipitation, enzyme-linked 
immunoassay and flow cytometry that rely exclusively on Ab’s are routine in most biomedical 
laboratories. In clinical settings, Ab’s are useful diagnostic markers providing evidence of 
infectious disease status and immunisation efficacy. Additionally, polyclonal Ab preparations have 
long been used as therapeutic/prophylactic agents with immune globulin (IVIg) still in frequent use 
[8]. These applications of polyclonal Ab’s rely on their specificity and sensitivity but it is becoming 
apparent that Ab’s are not as entirely specific or selective as first envisioned. The hope was that 
much of the difficulty associated with the mixtures of Ab specificity found with polyclonal 
reactivity could be alleviated through the use of monoclonal Ab’s [7]. Thus, many monoclonal Ab’s 
are now available for laboratory assays, having replaced polyclonal Ab’s and have become the 
fastest growing area in biotherapeutics with approximately 40 now approved by the United States’ 
FDA and Europe’s EMA [9].  
Since the original description of mouse monoclonal Ab’s in 1975 [3] the various methods for 
monoclonal Ab generation has amplified and the generation of numerous species of Ab’s including 
human clones is now possible [9]. Recombinant Ab’s, where the genes encoding a monoclonal Ab 
are expressed in vitro, are now becoming a dominant form of Ab production. It is relatively simple 
to produce recombinant Ab’s in a variety of expression systems such as mammalian, bacterial, 
yeast, insect, or plant cells once the original B cell clone has been selected [10], although 
glycosylation is known to vary and this may affect Ab functions [11]. Nevertheless, the use of 
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recombinant monoclonal Ab’s and traditional monoclonal Ab’s has improved some of the unwanted 
reactivity profiles that have been associated with polyclonal Ab’s, however monoclonal Ab’s are 
not exempt from cross reactivity and some have the ability to bind to a variety of unrelated self or 
foreign antigens through what is known as polyreactivity [12]. In fact, the term “Ab cross 
reactivity” suggests that each Ab binds to a primary epitope and that binding to any other epitope is 
an unwanted example of a lack of specificity. As summarized recently by Van Regenmortel [13], a 
variety of mechanisms can explain how a polyspecific Ab can bind to multiple epitopes. Therefore, 
an Ab combining site, or paratope, may be a rigid structure but allow interaction with different 
epitopes at different subsites in a process called rigid adaptation [14]. Alternatively, Ab paratopes 
may adopt multiple conformations through flexibility and bind to many different epitopes via an 
induced fit mechanism [15]. Finally, according to the differential ligand positioning model, a 
flexible Ab structure can bind diverse epitopes at different regions of the Ab combining site [16]. 
Together, these mechanisms can help explain the observed polyspecificity of numerous monoclonal 
Ab’s and the fact that polyclonal antiserum can sometimes outperform certain monoclonal Ab’s in 
specificity rankings. 
In the current study, a recombinant monoclonal Ab to m-ras (anti-m-ras) was generated by 
immunization of a rabbit with an m-ras C-terminal peptide followed by isolation of a single rabbit 
peripheral blood B cell secreting specific IgG and recombinant expression of the rabbit Ab genes in 
mammalian cells. We were using this monoclonal Ab to study ras proteins, an important family of 
intracellular molecular switches with roles in the regulation of cell growth, survival and 
differentiation [17]. The most well-known of these are the p21 ras proteins h-ras, n-ras, and k-ras 
that are often mutated in human cancers and are highly homologous to ras family members r-ras, m-
ras and rap and ral proteins [17].  Here we show that although the immunogen sequence used for 
immunization was specific to m-ras and the rabbit antisera and the recombinant anti-m-ras IgG 
bound to this peptide sequence somewhat specifically, upon further investigation it was found that 
the anti-m-ras IgG displayed cross reactivity. Thus, it bound both recombinant m-ras and the related 
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recombinant h-ras equally well despite the latter protein not containing the immunogen sequence. 
Further investigations reported within have revealed the potential molecular basis for the 
polyspecificity of this recombinant monoclonal Ab. These data add to the growing body of 
identified monoclonal Ab polyspecificity and consequently have important implications for 
interpretation of results obtained when relying on the specificity of monoclonal Ab’s. 
 
Materials and Methods 
Peptides and recombinant proteins 
Polypeptides used for immunization and used as antigens in ELISA and array blot experiments 
were generated by solid phase synthesis and were a gift from Dr Ian Clarke-Lewis (Biomedical 
Research Centre, Vancouver BC, Canada). Recombinant human m-ras and h-ras used as antigens in 
ELISA experiments were produced in bacteria as GST fusion proteins and were a gift from Gary 
Wilson (Biomedical Research Centre, Vancouver BC, Canada). The GST sequence was added to 
the N-terminus of m-ras and h-ras through the use of pGEX expression systems and was used as an 
affinity tag to purify the recombinant proteins using immobilized reduced glutathione and was not 
cleaved from the purified product [18].  
 Immunisation of rabbits and antisera  
Rabbits were injected with peptides corresponding to residues 187-204 
(KKKTKWRGDRATGTHKLQ) of m-ras fused to the C-terminus of the tetanus toxoid epitope 
QYIKANSKFIGITEL as described previously [19]. Antisera was obtained from peripheral blood 
and affinity purified as described [19]. 
Rabbit monoclonal Ab generation 
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The selected lymphocyte antibody method (SLAM) [20] was performed using peripheral blood 
lymphocytes from an immunized rabbit to isolate single rabbit B cells secreting IgG specific for m-
ras. Antibody variable (V) region gene segments were cloned from a single cell as described 
previously [20] and expressed as rabbit IgG following insertion into mammalian immunoglobulin 
expression vectors [21] modified to contain rabbit IgG constant (C) region genes [22]. Rabbit IgG 
was isolated from culture supernatants of transiently transfected HEK293 cells as described [22]. 
The anti-m-ras V region cDNA sequences were obtained by Sanger sequencing of the Ig expression 
plasmids using a CMV promoter primer at the University of British Columbia NAPS unit 
(Vancouver, BC, Canada).   
Enzyme-linked immuosorbent assay (ELISA) 
ELISA was performed as described previously [22]. Briefly, flat bottomed 96-well microtiter 
plates (Nunc Maxisorp) were coated with peptides or recombinant protein at a concentration of 1 
µg/ml in phosphate buffered saline (PBS) overnight at 4°C. The coating of different sized antigens 
at the same concentration will result in different densities of antigen depending upon their 
molecular weight and in-turn alters the binding curves obtained. Plates were then blocked with PBS 
containing 2% bovine serum albumin (BSA) at room temperature for 2 hours before addition of 
dilutions of rabbit antisera, culture supernatants containing rabbit IgG or affinity purified rabbit 
IgG. After an overnight incubation at 4°C the plates were washed with PBS containing 0.5% tween 
20 (PBST) and the bound rabbit IgG detected with goat anti-rabbit IgG alkaline phosphatase (AP) 
conjugate for 1 hour at 37°C. Plates were washed again with PBST and developed using para-
nitrophenyl phosphate (pNPP) substrate with the optical density measured at 405nm in a 
spectrophotometer. 
Peptide spot array blot 
An overlapping peptide array corresponding to the primary amino acid sequences of human m-
ras and h-ras was prepared by spotting peptides of 10 amino acid residues onto nitrocellulose 
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membranes (a gift from Dr Peter Schubert, Biomedical Research Centre, Vancouver, BC, Canada). 
Each subsequent spot overlapped with the sequence of the previous peptide spot by 8 amino acids 
such that the second peptide spot began with amino acid 3 of the ras sequences and the third peptide 
spot began with amino acid 5 etc. Thus the h-ras polypeptide was covered by 91 unique peptide 
spots whereas m-ras required 99 spots for complete coverage. Membranes were blocked with PBS 
containing 5% skim milk powder before the addition of diluted rabbit anti-m-ras Ab and incubated 
at 4°C overnight with shaking. The membranes were washed with PBST before the addition of 
secondary Ab anti-rabbit IgG horseradish peroxidase (HRP) conjugate. Washed membranes were 
covered with ECL substrate for 1 minute and spots developed by exposure to X-ray film. 
 
Results 
C-terminal regions of human m-ras and h-ras protein primary sequences were inspected for 
selection of peptides that displayed regions that could be exploited to generate m-ras specific Ab’s. 
Despite overall identity of 48.6% between human m-ras and h-ras, the C-terminal regions display 
much weaker identity (Figure 1A). Therefore, the region corresponding to amino acids 187-204 of 
human m-ras displayed just 21.7% identity to h-ras and was selected as being unique to m-ras 
(Figure 1B). Performing a NCBI Blast search using the 187-204 sequence of m-ras detected only m-
ras protein sequences from a variety of species, including rabbit, but not to other related ras 
proteins. It was therefore hypothesized that this sequence might be an epitope capable of eliciting 
m-ras specific Ab’s as the use of C-terminal peptides in immunization strategies results in Ab’s that 
bind native protein [23].  
Antisera was obtained from a rabbit immunized with the synthesized peptide corresponding to 
residues 187-204 of m-ras which had been fused to the C-terminus of the tetanus toxoid epitope to 
promote immunogenicity in rabbits. ELISA was performed to determine binding specificity and 
titer of this antisera. As shown in Figure 2, the rabbit antisera was very specific for the m-ras 
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peptide used as the immunogen with IgG binding still detectable at a dilution of approximately 
1:500 whereas IgG binding to the corresponding h-ras peptide was very weak at this dilution and 
was only observed at dilutions of antisera less than 1:10. 
Peripheral blood B cells were then obtained from the rabbit to generate an m-ras specific 
monoclonal Ab by the selected lymphocyte antibody method (SLAM) [20]. Sheep red blood cells 
coated with the m-ras peptide were used to identify and isolate single rabbit B cells producing 
specific antibodies. The immunoglobulin V regions of one selected clone were amplified by PCR 
and cloned into immunoglobulin expression vectors [21] that contained rabbit C regions [22] to 
generate a rabbit IgG clone specific for m-ras. The antibody V region predicted amino acid 
sequences obtained from plasmid cDNA sequencing were aligned with the nearest rabbit germ-line 
V region segments as defined by IMGT/V-QUEST [24]. These amino acid sequences and junctional 
rearrangements are shown in Figure 3. Analysis of the sequences revealed that the m-ras Vk 
sequence (Genbank accession number KX858713) was composed of the rearranged rabbit germline 
IGKV1S2*01 and IGKJ1-2*01 alleles with numerous somatic mutations clustered in the 
complementarity determining regions (CDR’s) which also corresponded to predicted antigen-
binding regions (ABRs) as determined by Paratome analysis [25, 26] (Fig 3A). The m-ras Vh 
sequence (Genbank accession number KX858712) was composed of the rearranged rabbit germline 
IGHV1S69*01, IGHD8-1*01 and IGHJ4*01 alleles with evidence of CDR-focused somatic 
mutations. The Vh CDR3 in particular contained at least five somatic mutations that resulted in 
negatively charged aspartic acid residues (Asp, D) within the sequence. Further analyses of the Vh 
and Vk junctions indicated that there was also the likelihood of significant junctional insertions in 
CDR3 of both the m-ras Vh and the m-ras Vk regions (Fig 3B). 
The monoclonal rabbit anti-m-ras IgG was produced by transient transfection of HEK293 cells 
with plasmids pLC-rbCκ(m-ras) and pHC-rbCγ1(m-ras) that contain the genes for rabbit anti-m-ras 
kappa light chains and gamma1 heavy chains respectively. Rabbit IgG in culture supernatants was 
then tested for binding specificity by ELISA. Binding to several peptides corresponding to C-
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terminal regions of m-ras (KKKTKWRGDRATGTHKLQ), r-ras2 
(ECPPSPEPTRKEKDKKGCHC) and h-ras (KLRKLNPPDESGPGCM) was first assessed. 
Significant and specific binding of anti-m-ras IgG was observed to the m-ras peptide but not to 
peptides of r-ras2 and h-ras (Fig 4). Control culture supernatant of untransfected HEK293 cells 
showed no binding to the m-ras peptide. Having confirmed that the anti-m-ras monoclonal IgG was 
specific for the m-ras C-terminal peptide, its ability to bind to recombinant ras proteins was next 
determined. Interestingly, we found that anti-m-ras rabbit IgG binds equally well to ELISA plates 
coated with m-ras or h-ras recombinant proteins (Fig 5A), despite the latter protein not containing 
the immunogen epitope sequence. In other sandwich ELISA experiments to confirm these data, 
these ras recombinant proteins were first captured with the plate-bound anti-ras scFv Y13-259 [27] 
and then detected using the rabbit anti-m-ras monoclonal Ab. It was found again that both m-ras 
and h-ras were bound equally by the anti-m-ras monoclonal Ab (Fig 5B) even though a significantly 
weaker signal was detected to both proteins, possibly due to steric hindrance by the Y13-259 
capture Ab. 
Concerned about the specificity of the anti-m-ras monoclonal Ab, the potential epitopes of both 
m-ras and h-ras that bound the rabbit IgG were mapped using an overlapping peptide array 
corresponding to the primary amino acid sequences of human m-ras and h-ras. Supplementary 
Figure 1 displays the peptides sequences spanning the m-ras and h-ras polypeptides. The data 
obtained with the ras peptides array and the anti-m-ras monoclonal IgG is shown in Figure 6. It can 
be readily seen that binding of the anti-m-ras IgG to peptide sequences of both h-ras and m-ras, 
above background reactivity with secondary Ab alone was observed. Additionally, there was clearly 
more binding to m-ras sequences than was detected to h-ras sequences. Thus, the anti-m-ras IgG 
bound strongly to the m-ras peptides spanning the C-terminal region (peptides 86-98) as expected 
but also to peptides spanning almost the entire remainder of the primary sequence (peptides 5-29, 
53-73, 77-82) with a few notable exclusions (peptides 1-3, 6, 14, 19, 20, 23-27, 58, 59, 72, 80, 87 
were not bound well). The region covered by peptides 30-52 was not bound by the anti-m-ras IgG 
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except for some weak binding to peptides 34, 42, 46, 48 and 51. Conversely, the anti-m-ras IgG 
bound to less of the h-ras primary sequence, favoring smaller regions covered by peptides proximal 
to the N-terminus (peptides 2-7 and 17-22), the middle of the sequence (peptides 40-57) and the C-
terminal region (peptides 71-85). There were large areas of the sequence not bound at all with 
notable exclusions being covered by peptides 24-39, 58-70 and the C-terminus 86-91. The strongest 
binding was observed to peptides 21, 22, 40, 49-51, 57, 72 and 81-84. To confirm these data 
visually by relating to the ras primary sequence, an analysis was performed comparing spot 
intensity to peptide sequence within the m-ras and h-ras sequence. Figure 7 shows these data as bar 
graphs representing spot intensity as a function of peptide sequence. Here it is readily observed that 
sections of the m-ras sequence covered by peptides 5-29 and 53-98 contain numerous peptides that 
are bound strongly whereas binding is restricted to much smaller regions (21-22, 49-51, 81-84) of 
h-ras with several notable single peptides (40, 57, 72) also bound well. The common feature of the 
majority of the h-ras and m-ras peptides bound by anti-m-ras IgG was the presence of positively 
charged amino acid residues arginine, lysine, and histidine. For example, binding to h-ras peptides 
was strongest in the regions of peptides 49-51, a sequence containing two lysine residues and two 
arginine residues, and also to peptides 81-84 that are particularly rich in both lysine and arginine 
residues. For m-ras, the strongest binding was observed in regions containing peptides 53-73 (13 
positively charged residues) and 86-98 (the C-terminal lysine-rich region). However, a minority of 
m-ras and h-ras peptides are not bound well even though they do contain at least one positively 
charged residue. For example h-ras peptides 19, 20, 58, 59, 73 and 74 each contain two positively 
charged residues but are not bound. This feature is less evident with m-ras, however peptides 83-85 
are not bound despite containing positive charged residues. In addition, some peptides are bound 
strongly although they do not contain positively charged residues (e.g. h-ras peptide 22; m-ras 
peptides 21, 28 and 29). These data offer potential explanations in molecular terms as to how the 
anti-m-ras monoclonal Ab was able to bind to both m-ras and h-ras recombinant proteins. 
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Discussion 
Here we have investigated the polyspecificity of a recombinant monoclonal Ab originally 
selected for binding to an m-ras specific peptide sequence that was rich in positively charged amino 
acid residues. The initial aim was to identify an m-ras specific polypeptide sequence and to use this 
to raise an m-ras specific monoclonal Ab. However, we found that the anti-m-ras monoclonal IgG 
bound to both h-ras and m-ras polypeptides despite being selected for binding to an m-ras specific 
C-terminal peptide sequence and the rabbit antisera that this clone was derived from was very 
specific for the m-ras peptide. More detailed epitope analyses demonstrated that the anti-m-ras 
monoclonal IgG also bound to numerous linear peptide sequences within both the m-ras and h-ras 
primary sequences and that the majority of these peptides contained positively charged amino acid 
residues, partially explaining the Ab polyspecificity. This ability of a monoclonal Ab to bind 
numerous and diverse peptide sequences that we describe here highlight the role of the Ab 
combining site in providing a structural paratope that has the ability to recognize and bind many 
different epitopes, effectively expanding the Ab repertoire to allow recognition of any antigen. The 
results also demonstrate that the precise analysis of data obtained when using monoclonal Ab’s for 
laboratory investigations involving protein detection is necessary as polyspecificity could give rise 
to numerous interpretations. 
A common approach for generating antisera or monoclonal Ab’s to a newly discovered protein, 
or to one where no suitable Ab reagents exist, is to immunize animals with a unique synthetic 
peptide found at the C-terminus of the primary sequence. This approach often results in specific 
Ab’s that bind the native protein [23] and that have bioactivity in vivo [28] although cross reactivity 
or polyspecificity is rarely investigated. In this study we identified a C-terminal region of human m-
ras that was unique amongst the known ras protein sequences and it was hypothesized that this 
sequence would elicit m-ras specific Ab’s when used as an immunogen. In fact, we found that 
antisera obtained from animals immunized with the m-ras peptide bound the m-ras immunogen 
peptide much more strongly than it did to the corresponding h-ras peptide sequence that is only 21% 
Page 10 of 19
John Wiley & Sons
Journal of Molecular Recognition
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
identical in primary sequence. Antisera binding to the h-ras peptide was detectable when undiluted 
but was lost at dilutions greater than 1:4 whereas binding to the m-ras peptide remained strong, 
even at antisera dilutions of 1:500. Thus, it was concluded that the antisera was “specific for m-ras” 
and would be a useful starting point for monoclonal Ab development. Following selection of a 
monoclonal Ab from this pool of Ab’s we found the Ab was capable of binding equally well to both 
the m-ras and h-ras polypeptides. Interestingly, the anti-m-ras monoclonal Ab did not display 
binding to the homologous lysine-rich peptide sequences of h-ras and r-ras2 whilst binding strongly 
to the m-ras immunizing peptide as shown in Figure 4. These important results are suggestive of 
these peptides not being promiscuously sticky, at least in ELISA experiments, and that the Ab is 
also not a universal binder. Taken together, these findings reinforce the often observed phenomenon 
that with protein Ag’s, polyclonal Ab’s and antisera are almost always more specific than 
monoclonal Ab’s. This is because protein Ag’s contain multiple epitopes and that all Ab’s to some 
degree are polyspecific, having the ability to bind to several and sometimes quite diverse epitopes. 
Thus, a polyclonal mixture of Ab’s will bind to numerous epitopes polyspecifically but the 
collective cross reactivity will be diluted out in such mixtures of Ab’s due to the common 
specificity to an immunodominant epitope. This phenomenon does not readily occur with single 
monoclonal Ab’s due to their selectivity for shorter epitopes and possible polyspecificity, 
theoretically explaining why polyclonal Ab mixtures often tend to be more specific than individual 
monoclonal Ab’s [13]. Our data shows that, even though the polyclonal antisera can bind both the 
m-ras and h-ras peptides, it is much more specific for the m-ras peptide whereas the isolated 
monoclonal Ab from that mixture is far less selective, binding to numerous and diverse peptide 
sequences.  
It is well established that the molecular interactions between Ab combining sites, which 
consists of six complementarity determining regions within the Ab Vh and Vl regions, and Ag 
epitopes are a series of weak noncovalent chemical bonds such as electrostatic interactions, 
hydrogen bonds, van der Waals forces, and hydrophobic interactions [29]. In addition, structural 
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considerations of both the Ab paratope and Ag epitope influence the strength and specificity of 
these interactions and can contribute to Ab cross reactivity and polyspecificity [30]. The data we 
have obtained for this monoclonal Ab suggest that electrostatic interactions between positively 
charged epitopes and a negatively charged Ab paratope may be an important factor in influencing 
the majority of polyspecific interactions and therefore the cross reactivity, although other 
interactions are also possible as not all peptides appeared to be bound via such electrostatic factors. 
Thus, immunization with a peptide containing numerous (7 out of 18, 39%) positively charged 
amino acid residues resulted in selection of an Ab clone that preferred interactions with such 
residues. Although it was not anticipated that a preferential selection of Ab’s that interact 
predominantly via these positive charges might occur, in hindsight it does seem likely, and could 
perhaps be exploited in the future to induce Ab polyspecificity via directed immunizations if 
desired.  
Analysis of the anti-m-ras Ab V region CDR sequences revealed that 4 of the 6 CDR’s 
(LCDR1, LCDR3, HCDR1, HCDR3) contained negatively charged amino acid residues that might 
interact with positively charged residues in the m-ras and h-ras epitopes. When looking at Ab 
paratopes, it is known that the HCDR3 contains the most diversity and forms the majority of 
contacts of Ab with Ag epitopes [31]. Interestingly the HCDR3 of the m-ras Ab contained 
numerous (5 out of 12, 42%) negatively charged amino acid residues that most likely resulted from 
somatic hypermutations brought about by positive selection through Ag binding. Furthermore, no 
positively charged amino acids were found in any of the 6 CDR’s of the anti-m-ras Ab suggesting 
that these residues were selected against. Clearly, in the absence of structural data confirming the 
precise interactions between the Ab paratope CDR residues and the various epitopes it is pure 
conjecture that such electrostatic interactions dictate the Ab polyspecificity, however similar 
supporting observations have been shown previously with autoreactive monoclonal Ab’s in mice 
[32]. Thus, our analyses of Ab V region sequences, coupled with the molecular observations of 
polyreactivity do help explain the molecular basis of the multispecificity of Ab’s in general and 
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specifically in this case, the ability of the anti-m-ras monoclonal Ab to bind numerous peptides of 
both m-ras and h-ras. 
When our investigations were expanded to a larger number of peptides we found that the anti-
m-ras IgG could bind to numerous unrelated sequences to the immunizing peptide sequence in 
addition to similar peptide sequences. The peptide sequences we investigated were based on the 
primary sequences of both m-ras and h-ras in an effort to understand how the monoclonal Ab was 
able to bind both of these proteins equally. As such, we did not investigate binding to unrelated 
peptide sequences although it can be argued that the homology of m-ras and h-ras is disparate 
enough to have provided enough diversity in the peptide sequences we analyzed and might reflect 
cross reactive binding to unrelated polypeptides. The most common feature of the epitopes bound, 
as outlined previously, was the cationic property of the peptides although other unrelated peptide 
sequences were also bound. Thus, a minority of peptides appeared to interact with the Ab in a 
manner other than through positive/negative charges, perhaps via primary sequence recognition, 
hydrophobicity, or even a structural basis. These data emphasize the likelihood that this particular 
monoclonal Ab is polyspecific with numerous detectable interactions occurring depending on the 
nature of the epitope. Thus, the anti-m-ras monoclonal IgG is capable of binding to numerous 
divergent peptide sequences but that the majority of these contain positively charged amino acid 
residues (K, R, and H), which perhaps not surprisingly, were also enriched in the m-ras immunizing 
peptide. These data also help explain in molecular terms how the monoclonal Ab was found to bind 
to both m-ras and h-ras recombinant proteins. 
In this study we performed heterogeneous immunoassays where binding of Ab’s in solution to 
the immobilized Ag/peptide were favored because a consistent approach in analyzing Ab’s binding 
to multiple epitopes was required. These assays therefore serendipitously allowed the description of 
some molecular details of the monoclonal Ab polyspecificity. Our analysis of the reactivity profile 
was limited to binding to a related ras recombinant protein and linear peptide sequences contained 
within ras proteins, although there is significant sequence divergence that would allow for 
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extrapolation of these results. It can be argued that our data obtained using small peptides somewhat 
selects for binding dominated by charged interactions and cannot be more broadly interpreted [33]. 
However, our initial multispecific observations were observed with larger recombinant ras protein 
sequences and therefore may be interpreted in a more biological context. It is also possible that the 
observed polyreactivity may be altered under different binding conditions and Ag availability that 
are used in other methods. Nevertheless, these differences in Ab behavior based on the analytical 
method used and the physical nature of the epitope(s) highlights some of the interpretation issues 
that are associated with the use of monoclonal Ab’s in immunoassays. Monoclonal Ab’s have found 
remarkable utility as laboratory reagents, analytical tools and more recently as therapeutic reagents 
that is largely based on their target selectivity and the specificity of their binding characteristics. It 
has also been estimated that around half of all commercially obtained Ab’s used in laboratories may 
bind to targets in addition to the one designed for [34]. This may be due to polyspecificity but the 
issue is often not investigated deeply unless discovered by chance. Additionally, differences in Ab 
reactivity profiles exist when using different analytical techniques and applications.  Clearly, some 
Ab’s prefer denatured targets to native configurations and others rely on fixing or chemical 
modifications for optimal specificity and perhaps even polyspecificty.  
In summary, our data have described the multispecificity of a recombinant monoclonal Ab that 
was discovered by chance. In this case, the data are suggestive of Ab multispecificty being 
regulated to a large degree by electrostatic interactions between a negatively charged Ab paratope 
and positively charged epitopes. Future experiments beyond what is possible in the current 
manuscript that would prove this theory would involve mutagenesis studies of the acidic residues 
found in the anti-m-ras Ab to probe the polyspecificity profile and modifications of basic residues 
in specific h-ras peptides may to confirm that the molecular nature of the cross reactivity is 
predominantly due to positive-negative charge interactions. Although this is just one example of Ab 
multispecificity, the phenomenon can be generally applied to monoclonal Ab’s and question current 
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vaccine engineering attempts relying on structure-guided epitope recognition by neutralizing Ab’s 
[35]. 
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Figure 1: Alignments of m-ras and h-ras primary amino acid sequences.  
 
(A) m-ras (upper) complete amino acid sequence aligned to that of h-ras (lower). Spaces represent gaps in 
the alignment and conserved residues are highlighted by grey boxes (101 of 208 residues, 48.6% identity). 
Numbering is based upon m-ras primary sequence. (B) Alignment of C-terminal regions (186-208) of m-
ras (upper) and corresponding region of h-ras (lower) with bolded residues representing sequences used for 
immunisation of rabbits and in peptide ELISA experiments (m-ras only). Grey boxes indicate that just 5 of 
23 residues (21.7% identity) are conserved. 
 
Figure 2: ELISA to determine binding of rabbit antiserum to h-ras and m-ras peptides. 
 
Diluted rabbit antiserum from an immunised rabbit was allowed to bind to plate-bound C-terminal m-ras 
peptide (KKKTKWRGDRATGTHKLQ) or the corresponding h-ras peptide (KLRKLNPPDESGPGCM) 
before bound rabbit IgG was detected. 
 
 
Figure 3: Amino acid and nucleotide alignments of rabbit anti-mras mAb variable regions. 
 
The rabbit anti-mras monoclonal antibody variable region sequences (mrasVk and mrasVh) are aligned 
with the closest rabbit germ-line segments as determined by IMGT/V-QUEST. (A) The anti-mras V region 
amino acid sequences are shown above the most likely germ-line sequences. Identical residues are shown 
with (-) and inserted or mutated residues highlighted in bold. Complementarity determining regions 
(CDR’s) are highlighted grey and potential antigen-binding regions (ABRs) underlined. (B) The anti-mras 
V region CDR3 sequences are shown above the nucleotide sequence and most likely germ-line gene 
segment used during rearrangement. Mutated nucleotides and amino acid residues are shown in bold and 
junctional regions where N-nucleotide addition could have resulted are highlighted.  
 
Figure 4: ELISA to determine binding of rabbit anti-m-ras mAb to h-ras, r-ras2 and m-ras peptides. 
 
Diluted culture supernatants containing rabbit mAb derived from an immunised rabbit was allowed to bind 
to plate-bound C-terminal m-ras peptide (KKKTKWRGDRATGTHKLQ), r-ras2 peptide 
(ECPPSPEPTRKEKDKKGCHC) or the corresponding h-ras peptide (KLRKLNPPDESGPGCM) before 
bound rabbit IgG was detected. Control refers to untransfected culture supernatant binding to plate-bound 
C-terminal m-ras peptide. 
 
Figure 5: ELISA to determine binding of rabbit anti-m-ras mAb to recombinant h-ras and m-ras. 
 
(A) Diluted purified rabbit mAb from an immunised rabbit was allowed to bind to plate-bound 
recombinant m-ras or to recombinant h-ras before bound rabbit IgG was assessed. (B) Recombinant h-ras 
and m-ras were captured with plate-bound scFv Y13-259 and diluted rabbit mAb (squares) or rabbit 
antisera (circles) added before bound rabbit IgG was assessed. 
 
 
 
 
 
Page 18 of 19
John Wiley & Sons
Journal of Molecular Recognition
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Figure 6: Peptide spot array of h-ras and m-ras. 
 
Binding of anti-rabbit IgG (secondary Ab only) and anti-mras mAb followed by secondary Ab (anti-mras 
mAb) to h-ras peptides (upper) and m-ras peptides (lower). Numbering refers to peptide # and sequence 
shown in Supplementary Figure 1. The primary sequence of h-ras is shorter so 91 peptides span this 
polypeptide whereas 99 peptides are required to span the entire m-ras polypeptide. 
 
Figure 7: Analysis of peptide spot array data. 
 
The h-ras (upper) and m-ras (lower) primary sequences are displayed with the overlapping peptides used in 
Figure 6 and shown in Supplementary Figure 1, represented by a line underneath. Binding of the anti-mras 
monoclonal IgG is represented as the relative spot intensity obtained (Fig 6). Each bar represents the level 
of IgG binding to the peptide and is aligned to the first residue of the peptide on the x-axis i.e. for h-ras the 
first peptide with discernible binding was peptide 2 beginning with E, whereas for m-ras the first is peptide 
4 beginning with P. 
 
Supplementary Figure 1: Sequences of h-ras and m-ras peptide spots used in Figure 6. 
 
 
Page 19 of 19
John Wiley & Sons
Journal of Molecular Recognition
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
